SynthesisInflammopharmacology2026
Effect of Quercetin on inflammatory markers in diabetes mellitus: a systematic review and meta-analysis of animal studies.
Synthesis in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiabetes mellitus (DM) is associated with severe complications driven by chronic inflammation, which releases cytokines, chemokines, and adhesion molecules. Herbal medicines are gaining importance due to fewer drug-related adverse effects. Quercetin is a flavonoid with potent anti-inflammatory and antioxidant properties. This systematic review and meta-analysis aim to evaluate the impact of Quercetin on inflammatory markers in the animal model of diabetes.
methodsA comprehensive literature search was conducted in PubMed, Embase, Web of Science and Google Scholar from inception to February 2025, to identify relevant preclinical studies. Diabetic rodents were included, whereas in vitro, ex vivo, and non-rodent studies were excluded. A meta-analysis using a random-effects model (RE) was performed to calculate standardised mean differences (SMD) with 95% confidence intervals. Methodological quality was assessed by sensitivity analyses, publication bias and SYRCLE risk of bias.
resultThe included 14 studies in this systematic literature review and meta-analysis indicates that Quercetin treatment significantly reduces the TNF-α (SMD: - 3.40, 95% CI - 5.17 to - 1.63) (P = 0.0002), IL-1β (SMD: - 1.57, 95% CI - 2.65 to - 0.49) (P = 0.004) and IL-6 (SMD: - 4.28, 95% CI - 5.86 to - 2.70) (P < 0.00001). Possible publication bias and moderate-to-substantial heterogeneity (I
conclusionThe present meta-analysis demonstrates that Quercetin treatment significantly reduces the inflammatory markers in diabetic animal models. These findings provide a strong preclinical foundation for further clinical research, highlighting Quercetin as a potential treatment to mitigate inflammation-driven complications in diabetes.
Indexed as
Identifiers
41396378What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.